On August 12, Altimmune (NASDAQ:ALT) reported second quarter results that read less like a routine earnings update and more like a status check on three separate diseases at the same time. The clinical-stage biopharmaceutical company disclosed a newly launched global Phase 3 trial in MASH, positive Phase 2 data in alcohol use disorder, and completed enrollment in a Phase 2 trial for alcohol-associated liver disease, all inside one release. None of the three programs has reached the finish line, and the company still has no approved product generating revenue.
A Pipeline Hitting Its Marks
Pemvidutide’s furthest-along program is in MASH, where the FDA granted Breakthrough Therapy Designation based on 24-week data from the earlier IMPACT Phase 2b trial. That designation set up the global PERFORMA Phase 3 study, which Altimmune initiated in August, though a 52-week data readout is not expected until 2029. The nearer-term story is alcohol use disorder, where the company reported positive topline results from its RECLAIM Phase 2 trial in July. The 100-patient, 24-week study hit its primary endpoint, a statistically significant and clinically meaningful drop in heavy drinking days, and also cleared two secondary endpoints the FDA recognizes as registrational: a 2-level reduction in WHO-risk drinking levels and zero heavy drinking days.
Safety and tolerability came back favorable; the FDA granted Fast Track designation, and Altimmune now plans to request an End-of-Phase 2 meeting with the agency while engaging European regulators. In the third program, alcohol-associated liver disease, the company completed enrollment in its RESTORE Phase 2 trial in July and amended the protocol to better capture liver benefit after a full year of treatment. Cash and investments stood at $519 million as of June 30, supported by an oversubscribed April offering that raised $225 million.
The Money Keeps Going Out
Running three mid-to-late-stage trials at once costs money, and Altimmune’s spending is climbing to match. Research and development expenses rose to $18.7 million for the quarter ended June 30, up from $17.2 million in the same period of 2025, with the ALD trial and PERFORMA startup costs driving the increase even as IMPACT-related spending rolled off. General and administrative costs jumped further, to $7.6 million from $5.7 million a year earlier, on higher professional services and compensation expenses.
The net loss for the quarter reached $22.8 million, slightly ahead of the $22.1 million lost in the same period of 2025, even though a larger share count from the April raise pushed the per-share loss down to $0.12 from $0.27. The bigger issue is time. RESTORE’s topline data is not due until the second half of 2027, and PERFORMA’s readout is four years away. Meanwhile, the company is relocating its headquarters to Morristown, New Jersey later in 2026, an added cost for a business that still books zero product revenue.
Wall Street’s Mixed Signals
Hedge fund ownership climbed from 23 funds to 40 in the most recent quarter, a jump that reads as growing institutional conviction in the story. That optimism sits awkwardly next to a short interest of 26.24% of float, a level that signals a substantial bear camp still betting against the stock. A gap that wide between rising fund ownership and heavy short positioning suggests the market has not settled on what the recent trial news is actually worth.
Where The Debate Goes Next
Altimmune enters the back half of 2026 with three trials in motion, a $519 million cash cushion, and a stock that funds are buying while short sellers keep piling in. For the bulls, the case rests on RECLAIM’s clean hit on registrational endpoints translating into a workable regulatory path for AUD. For the bears, rising R&D and G&A spending against years-away readouts in MASH and ALD is the more pressing fact. Nothing here resolves that tension, since the next real catalyst, an FDA meeting outcome on AUD, has not yet happened.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center